Effects of a leukotriene receptor antagonist on exhaled leukotriene E 4 and prostanoids in children with asthma

Paolo Montuschi, Chiara Mondino, Pierluigi Koch, Peter J. Barnes, Giovanni Ciabattoni

Research output: Contribution to journalArticle

Abstract

Background: Leukotriene (LT) E 4 and 8-isoprostane concentrations are elevated in exhaled breath condensate in children with asthma. The effects of leukotriene receptor antagonists (LTRAs) on exhaled leukotriene and prostanoids in children with asthma are unknown. Objective: (1) To study the effect of montelukast, a LTRA, on exhaled LTE 4, 8-isoprostane, and prostaglandin E 2 in children with asthma and atopic children; (2) to measure exhaled nitric oxide. Methods: An open-label study with oral montelukast (5 mg once daily for 4 weeks) was undertaken in 17 atopic children with asthma and 16 atopic children without asthma. Results: Pretreatment exhaled LTE 4 (P <.0001) and 8-isoprostane (P <.0001) values were higher in atopic children with asthma than in atopic children without asthma. In atopic children with asthma, montelukast reduced exhaled LTE 4 by 33% (P <.001), and this reduction was correlated with pretreatment LTE 4 values (r = -0.90; P = .0001). Posttreatment exhaled LTE 4 levels in children with asthma were higher than pretreatment LTE 4 values in atopic children without asthma (P <.004). Montelukast had no effect on exhaled LTE 4 in atopic children without asthma (P = .74), or on exhaled 8-isoprostane (atopic children with asthma, P = .94; atopic children without asthma, P = .55) and PGE 2 (atopic children with asthma, P = .56; atopic children without asthma, P = .93) in both groups. In atopic children with asthma, exhaled nitric oxide concentrations were reduced by 27% (P <.05) after montelukast. Conclusion: Leukotriene receptor antagonists decrease exhaled LTE 4 in atopic children with asthma. This reduction is dependent on baseline exhaled LTE 4 values. Clinical implications: Measurement of exhaled LTE 4 might help identify children with asthma most likely to benefit from LTRAs.

Original languageEnglish
Pages (from-to)347-353
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume118
Issue number2
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Leukotriene E4
Leukotriene Antagonists
Prostaglandins
Asthma
montelukast
8-epi-prostaglandin F2alpha
Prostaglandins E
Nitric Oxide

Keywords

  • airway inflammation
  • childhood asthma
  • exhaled breath condensate
  • exhaled nitric oxide
  • Leukotriene E
  • leukotriene receptor antagonists
  • noninvasive markers
  • prostanoids

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Effects of a leukotriene receptor antagonist on exhaled leukotriene E 4 and prostanoids in children with asthma. / Montuschi, Paolo; Mondino, Chiara; Koch, Pierluigi; Barnes, Peter J.; Ciabattoni, Giovanni.

In: Journal of Allergy and Clinical Immunology, Vol. 118, No. 2, 08.2006, p. 347-353.

Research output: Contribution to journalArticle

Montuschi, Paolo ; Mondino, Chiara ; Koch, Pierluigi ; Barnes, Peter J. ; Ciabattoni, Giovanni. / Effects of a leukotriene receptor antagonist on exhaled leukotriene E 4 and prostanoids in children with asthma. In: Journal of Allergy and Clinical Immunology. 2006 ; Vol. 118, No. 2. pp. 347-353.
@article{223799a7494e4b3fba8dd9cd9c0777b9,
title = "Effects of a leukotriene receptor antagonist on exhaled leukotriene E 4 and prostanoids in children with asthma",
abstract = "Background: Leukotriene (LT) E 4 and 8-isoprostane concentrations are elevated in exhaled breath condensate in children with asthma. The effects of leukotriene receptor antagonists (LTRAs) on exhaled leukotriene and prostanoids in children with asthma are unknown. Objective: (1) To study the effect of montelukast, a LTRA, on exhaled LTE 4, 8-isoprostane, and prostaglandin E 2 in children with asthma and atopic children; (2) to measure exhaled nitric oxide. Methods: An open-label study with oral montelukast (5 mg once daily for 4 weeks) was undertaken in 17 atopic children with asthma and 16 atopic children without asthma. Results: Pretreatment exhaled LTE 4 (P <.0001) and 8-isoprostane (P <.0001) values were higher in atopic children with asthma than in atopic children without asthma. In atopic children with asthma, montelukast reduced exhaled LTE 4 by 33{\%} (P <.001), and this reduction was correlated with pretreatment LTE 4 values (r = -0.90; P = .0001). Posttreatment exhaled LTE 4 levels in children with asthma were higher than pretreatment LTE 4 values in atopic children without asthma (P <.004). Montelukast had no effect on exhaled LTE 4 in atopic children without asthma (P = .74), or on exhaled 8-isoprostane (atopic children with asthma, P = .94; atopic children without asthma, P = .55) and PGE 2 (atopic children with asthma, P = .56; atopic children without asthma, P = .93) in both groups. In atopic children with asthma, exhaled nitric oxide concentrations were reduced by 27{\%} (P <.05) after montelukast. Conclusion: Leukotriene receptor antagonists decrease exhaled LTE 4 in atopic children with asthma. This reduction is dependent on baseline exhaled LTE 4 values. Clinical implications: Measurement of exhaled LTE 4 might help identify children with asthma most likely to benefit from LTRAs.",
keywords = "airway inflammation, childhood asthma, exhaled breath condensate, exhaled nitric oxide, Leukotriene E, leukotriene receptor antagonists, noninvasive markers, prostanoids",
author = "Paolo Montuschi and Chiara Mondino and Pierluigi Koch and Barnes, {Peter J.} and Giovanni Ciabattoni",
year = "2006",
month = "8",
doi = "10.1016/j.jaci.2006.04.010",
language = "English",
volume = "118",
pages = "347--353",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of a leukotriene receptor antagonist on exhaled leukotriene E 4 and prostanoids in children with asthma

AU - Montuschi, Paolo

AU - Mondino, Chiara

AU - Koch, Pierluigi

AU - Barnes, Peter J.

AU - Ciabattoni, Giovanni

PY - 2006/8

Y1 - 2006/8

N2 - Background: Leukotriene (LT) E 4 and 8-isoprostane concentrations are elevated in exhaled breath condensate in children with asthma. The effects of leukotriene receptor antagonists (LTRAs) on exhaled leukotriene and prostanoids in children with asthma are unknown. Objective: (1) To study the effect of montelukast, a LTRA, on exhaled LTE 4, 8-isoprostane, and prostaglandin E 2 in children with asthma and atopic children; (2) to measure exhaled nitric oxide. Methods: An open-label study with oral montelukast (5 mg once daily for 4 weeks) was undertaken in 17 atopic children with asthma and 16 atopic children without asthma. Results: Pretreatment exhaled LTE 4 (P <.0001) and 8-isoprostane (P <.0001) values were higher in atopic children with asthma than in atopic children without asthma. In atopic children with asthma, montelukast reduced exhaled LTE 4 by 33% (P <.001), and this reduction was correlated with pretreatment LTE 4 values (r = -0.90; P = .0001). Posttreatment exhaled LTE 4 levels in children with asthma were higher than pretreatment LTE 4 values in atopic children without asthma (P <.004). Montelukast had no effect on exhaled LTE 4 in atopic children without asthma (P = .74), or on exhaled 8-isoprostane (atopic children with asthma, P = .94; atopic children without asthma, P = .55) and PGE 2 (atopic children with asthma, P = .56; atopic children without asthma, P = .93) in both groups. In atopic children with asthma, exhaled nitric oxide concentrations were reduced by 27% (P <.05) after montelukast. Conclusion: Leukotriene receptor antagonists decrease exhaled LTE 4 in atopic children with asthma. This reduction is dependent on baseline exhaled LTE 4 values. Clinical implications: Measurement of exhaled LTE 4 might help identify children with asthma most likely to benefit from LTRAs.

AB - Background: Leukotriene (LT) E 4 and 8-isoprostane concentrations are elevated in exhaled breath condensate in children with asthma. The effects of leukotriene receptor antagonists (LTRAs) on exhaled leukotriene and prostanoids in children with asthma are unknown. Objective: (1) To study the effect of montelukast, a LTRA, on exhaled LTE 4, 8-isoprostane, and prostaglandin E 2 in children with asthma and atopic children; (2) to measure exhaled nitric oxide. Methods: An open-label study with oral montelukast (5 mg once daily for 4 weeks) was undertaken in 17 atopic children with asthma and 16 atopic children without asthma. Results: Pretreatment exhaled LTE 4 (P <.0001) and 8-isoprostane (P <.0001) values were higher in atopic children with asthma than in atopic children without asthma. In atopic children with asthma, montelukast reduced exhaled LTE 4 by 33% (P <.001), and this reduction was correlated with pretreatment LTE 4 values (r = -0.90; P = .0001). Posttreatment exhaled LTE 4 levels in children with asthma were higher than pretreatment LTE 4 values in atopic children without asthma (P <.004). Montelukast had no effect on exhaled LTE 4 in atopic children without asthma (P = .74), or on exhaled 8-isoprostane (atopic children with asthma, P = .94; atopic children without asthma, P = .55) and PGE 2 (atopic children with asthma, P = .56; atopic children without asthma, P = .93) in both groups. In atopic children with asthma, exhaled nitric oxide concentrations were reduced by 27% (P <.05) after montelukast. Conclusion: Leukotriene receptor antagonists decrease exhaled LTE 4 in atopic children with asthma. This reduction is dependent on baseline exhaled LTE 4 values. Clinical implications: Measurement of exhaled LTE 4 might help identify children with asthma most likely to benefit from LTRAs.

KW - airway inflammation

KW - childhood asthma

KW - exhaled breath condensate

KW - exhaled nitric oxide

KW - Leukotriene E

KW - leukotriene receptor antagonists

KW - noninvasive markers

KW - prostanoids

UR - http://www.scopus.com/inward/record.url?scp=33746727618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746727618&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2006.04.010

DO - 10.1016/j.jaci.2006.04.010

M3 - Article

C2 - 16890757

AN - SCOPUS:33746727618

VL - 118

SP - 347

EP - 353

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2

ER -